Riskpilot← Back to searchSign inGet full accessNinex AB
ABActiveOrg 5565457032Stockstigen 13Wholesale of pharmaceutical and medical goods · NACE 4646Est. 19970 employees
Revenue 2024
SEK 0
EBITDA margin
—
-46% vs 2023
Equity ratio
26.0%
Financial strength
Net profit 2024
SEK 12,1M
+243% vs 2023
| Revenue | SEK 0 | — |
| EBITDA | SEK -3,7M | -46% |
| Net profit | SEK 12,1M | +243% |
| Total assets | SEK 214M | +63% |
| Equity | SEK 55,6M | +4% |
| Employees | 0 | — |
Legal name
Ninex AB
Org number
5565457032
Legal form
Aktiebolag
NACE code
4646 · Wholesale of pharmaceutical and medical goods
Founded
2 september 1997
Share capital
SEK 100 000
Employees
0
VAT registered
Yes
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Firman tecknas av styrelsen
Company purpose
Aktiebolagets verksamhet ska vara att direkt eller indirekt, äga aktier i verksamheter vilka tillverkar produkter och komponenter inom affärsområdet Medicinsk teknik samt därmed förenlig verksamhet.
Address
Stockstigen 13
Email
lars.kvarnhem@priego.se
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Staff expenses | — | — | — | — | — | — | — | — | — | — |
| EBITDA | −13 | −15 | −14 | −1 | −71 | −83 | −27 | −51 | −2 501 | −3 656 |
| Depreciation & amort. | −0 | −0 | −0 | −0 | −0 | −0 | −0 | — | — | −0 |
| EBIT | −13 | −15 | −14 | −1 | −71 | −83 | −27 | −51 | −2 501 | −3 656 |
| Net financials | — | — | — | — | 15 148 | −431 | 448 | 24 838 | −5 948 | 15 713 |
| Profit before tax | −13 | −15 | −14 | −1 | 15 078 | −514 | 421 | 24 787 | −8 449 | 12 057 |
| Tax | −0 | −0 | −0 | −0 | −0 | −0 | −0 | — | — | −0 |
| Net profit | −13 | −15 | −14 | −1 | 15 078 | −514 | 421 | 24 787 | −8 449 | 12 057 |
| Item | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | 130 | 115 | 118 | 117 | 63 050 | 79 854 | 84 642 | 110 816 | 131 366 | 213 998 |
| Equity | 109 | 94 | 79 | 78 | 27 155 | 36 776 | 37 197 | 61 984 | 53 534 | 55 591 |
| Long-term debt | 0 | 0 | 0 | 0 | 35 867 | 37 444 | 41 834 | 44 068 | 77 455 | 118 494 |
| Short-term debt | 21 | 21 | 39 | 39 | 28 | 5 633 | 5 611 | 4 765 | 377 | 39 913 |
| Total debt | 21 | 21 | 39 | 39 | 35 895 | 43 077 | 47 445 | 48 833 | 77 832 | 158 407 |
EBITDA margin
-365600000.0%
This company
15.8%
Market median
-2313924151% vs market
20152024
Equity ratio
26.0%
This company
38.2%
Market median
-32% vs market
20152024
Return on equity
21.7%
This company
18.4%
Market median
+18% vs market
20152024
Net profit margin
1205700000.0%
This company
8.1%
Market median
+14885185085% vs market
20152024
Asset turnover
0.00×
This company
1.12×
Market median
-100% vs market
20152024
Debt / equity
2.85×
This company
0.62×
Market median
-360% vs market
20152024
- Annual report 2024Filed via Bolagsverket / SCB · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Bolagsverket / SCB · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Bolagsverket / SCB · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Bolagsverket / SCB · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via Bolagsverket / SCB · Period 2020-01-01 – 2020-12-31
- Annual report 2019Filed via Bolagsverket / SCB · Period 2018-09-01 – 2019-12-31
- Annual report 2018Filed via Bolagsverket / SCB · Period 2017-09-01 – 2018-08-31
- Annual report 2017Filed via Bolagsverket / SCB · Period 2016-09-01 – 2017-08-31
- Annual report 2016Filed via Bolagsverket / SCB · Period 2015-09-01 – 2016-08-31
- Annual report 2015Filed via Bolagsverket / SCB · Period 2014-09-01 – 2015-08-31
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
BE | Audit | 2022 | — | — |
LJ Audit | Audit | 2022 | — | — |
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
| Deputy Board Member | 2022 | — | — | |
| Board of Directors | 2022 | — | — | |
| Chairman | 2022 | — | — |
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
Ninex AB (this company)
Reison Medical ABBoard members of Ninex AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Björn Erik Eketrä Hallander | Audit | 0 companies |
| Lars Johan Rudengren | Audit | 0 companies |
| Madeleine Anna Margaretha Kvarnhem | Deputy Board Member | 0 companies |
| Bengt Åke Julander | Board of Directors | 0 companies |
| Lars Tommy Kvarnhem | Chairman | 0 companies |